Table 4.

The duration of sick leave difference between patients with revision surgery and omalizumab treatment

Characteristics	Revision surgery (N = 22)	Omalizumab (N = 22)	P value
Total duration of outpatient visits (hours), median (IQR)	24.00 (9.00–78.00)	24.00 (12.00–28.50)	0.9488
Total duration of hospitalization (hours), median (IQR)	168.00 (138.00–192.00)	/	/
Total duration of postoperative (hours), median (IQR)	336.00 (336.00–336.00)	/	/
Total duration of disease-related (hours), median (IQR)	547.50 (509.00–600.00)	24.00 (12.00–28.50)	< 0.0001∗

∗, P < 0.05. IQR, interquartile range. The data was the total duration in six-month follow-up period